BPC
KYMR icon

Bryce Point Capital’s Kymera Therapeutics KYMR Stock Holding History

Bryce Point Capital’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$335K Buy
+5,921
New +$267K 0.41% 141

Other funds holding KYMR

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Bryce Point Capital's KYMR Position: Q3 2025 in Review

Bryce Point Capital opened a new position in Kymera Therapeutics (KYMR) in Q3 2025: 5,921 shares worth $335K. The stake represents 0.41% of the portfolio and ranks #141 among its holdings.

210 funds tracked by Wall St. Rank hold KYMR as of Q3 2025.

  • Bryce Point Capital held 5,921 shares of Kymera Therapeutics worth $335K as of Q3 2025.
  • Kymera Therapeutics was a new Bryce Point Capital position in Q3 2025.
  • Kymera Therapeutics made up 0.41% of Bryce Point Capital's portfolio in Q3 2025, its #141 holding.
  • 210 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2025.

Based on Bryce Point Capital's 13F filing for Q3 2025, filed 6 Nov 2025.